Repository logo
 

Isthmin-2 is essential for extravillous trophoblast invasion and is a first trimester predictor of preeclampsia and fetal growth restriction

Accepted version
Peer-reviewed

Repository DOI


Change log

Abstract

Preeclampsia (PE) and fetal growth restriction (FGR) are major causes of global morbidity and mortality. Both conditions are associated with impaired invasion of the uterus by extravillous trophoblast (EVT). We performed proteomics in maternal serum obtained at ~12 weeks of gestational in a prospective pregnancy cohort (POPS). Here we show that low maternal serum isthmin-2 (ISM2) was the strongest protein signal (out of 2,904) in the first trimester of pregnancy for PE or FGR. We validated the association in two independent cohorts (POPS2 and IMPACT). ISM2 protein and mRNA are almost exclusively produced in the placenta and, within the placenta, ISM2 mRNA is highly enriched in EVT. Knocking down ISM2 in cultured human trophoblast stem cells profoundly inhibited EVT invasion. Conversely, expressing ISM2 in a cell line lacking endogenous ISM2 (HEK293 cells) promoted migration. We conclude that ISM2 may be causally involved in the early pathophysiology of failed trophoblast invasion and that the protein and its associated pathways are potential targets for the prediction and prevention of PE and FGR.

Description

Keywords

Journal Title

Nature Medicine

Conference Name

Journal ISSN

1078-8956
1546-170X

Volume Title

Publisher

Nature Research

Publisher DOI

Publisher URL

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Cambridge University Hospitals NHS Foundation Trust (CUH) (RG52380)
Wellcome Leap (Unknown)
Cambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
Wellcome Trust (UNS76944)
This work was supported by the Wellcome Leap In Utero programme and a grant from the Wellcome Trust (POPS2) 215524/Z/19/Z. The Pregnancy Outcome Prediction study was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (first two cycles, 2007-2017, Women’s Health theme). IA is funded by the UKRI/MRC career development award (MR/W027046/1) and UKRI/MRC research grant (MR/Z504440/1). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The IMPACT study was supported by Swedish government (ALF) and several Regions (YC 931960, YC 968567, YC 979810, LB RFR839171, LB CKFUU795621, AS FoUI-954134, YC ALFGBG-77860, 1005092, AKW ALF-Uppsala), The Swedish Medical Society (YC 2022), Frimurarfonden Barnhusdirektionen (YC GLS 7000991), Swedish Society of Medicine (AS FoUI-971120), Wilhelm och Martina Lundgren foundation (YC 2018-2094), Swedish Research Council (AKW 2024-02584, SL 2025- 02475).